753 related articles for article (PubMed ID: 26634561)
21. The Content Validity of a Chemotherapy-Induced Peripheral Neuropathy Patient-Reported Outcome Measure.
Lavoie Smith EM; Haupt R; Kelly JP; Lee D; Kanzawa-Lee G; Knoerl R; Bridges C; Alberti P; Prasertsri N; Donohoe C
Oncol Nurs Forum; 2017 Sep; 44(5):580-588. PubMed ID: 28820525
[TBL] [Abstract][Full Text] [Related]
22. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.
Beijers AJ; Mols F; Tjan-Heijnen VC; Faber CG; van de Poll-Franse LV; Vreugdenhil G
Acta Oncol; 2015 Apr; 54(4):463-9. PubMed ID: 25417732
[TBL] [Abstract][Full Text] [Related]
23. Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS).
Binda D; Vanhoutte EK; Cavaletti G; Cornblath DR; Postma TJ; Frigeni B; Alberti P; Bruna J; Velasco R; Argyriou AA; Kalofonos HP; Psimaras D; Ricard D; Pace A; Galiè E; Briani C; Dalla Torre C; Lalisang RI; Boogerd W; Brandsma D; Koeppen S; Hense J; Storey D; Kerrigan S; Schenone A; Fabbri S; Rossi E; Valsecchi MG; Faber CG; Merkies IS; ; Galimberti S; Lanzani F; Mattavelli L; Piatti ML; Bidoli P; Cazzaniga M; Cortinovis D; Lucchetta M; Campagnolo M; Bakkers M; Brouwer B; Boogerd W; Grant R; Reni L; Piras B; Pessino A; Padua L; Granata G; Leandri M; Ghignotti I; Plasmati R; Pastorelli F; Heimans JJ; Eurelings M; Meijer RJ; Grisold W; Lindeck Pozza E; Mazzeo A; Toscano A; Russo M; Tomasello C; Altavilla G; Penas Prado M; Dominguez Gonzalez C; Dorsey SG
Eur J Cancer; 2013 Sep; 49(13):2910-8. PubMed ID: 23668917
[TBL] [Abstract][Full Text] [Related]
24. Chemotherapy-Induced Peripheral Neuropathy (CIPN) as a Predictor of Decreased Quality of Life in Testicular Germ Cell Tumor Survivors.
Orszaghova Z; Galikova D; Lesko P; Obertova J; Rejlekova K; Sycova-Mila Z; Palacka P; Kalavska K; Svetlovska D; Mladosievicova B; Mardiak J; Mego M; Chovanec M
Clin Genitourin Cancer; 2024 Jun; 22(3):102067. PubMed ID: 38555680
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry.
Mols F; Beijers T; Lemmens V; van den Hurk CJ; Vreugdenhil G; van de Poll-Franse LV
J Clin Oncol; 2013 Jul; 31(21):2699-707. PubMed ID: 23775951
[TBL] [Abstract][Full Text] [Related]
26. Reliability and validity of the Korean version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire to assess Chemotherapy-induced peripheral neuropathy.
Kim HY; Kang JH; Youn HJ; So HS; Song CE; Chae SY; Jung SH; Kim SR; Kim JY
J Korean Acad Nurs; 2014 Dec; 44(6):735-42. PubMed ID: 25608551
[TBL] [Abstract][Full Text] [Related]
27. Development and validation of the chemotherapy-induced peripheral neuropathy integrated assessment - oxaliplatin subscale: a prospective cohort study.
Gu Z; Chen C; Gu J; Song Z; Wei G; Cai G; Shu Q; Zhu L; Zhu W; Deng H; Li S; Chen A; Yin Y; Wu Q; Zhu H; Li G; Dai A; Huo J
BMC Cancer; 2023 Nov; 23(1):1109. PubMed ID: 37964212
[TBL] [Abstract][Full Text] [Related]
28. Reflexology in the management of chemotherapy induced peripheral neuropathy: A pilot randomized controlled trial.
Kurt S; Can G
Eur J Oncol Nurs; 2018 Feb; 32():12-19. PubMed ID: 29353627
[TBL] [Abstract][Full Text] [Related]
29. Psychometric testing of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy.
Cheng HL; Lopez V; Lam SC; Leung AKT; Li YC; Wong KH; Au JSK; Sundar R; Chan A; De Ng TR; Suen LKP; Chan CW; Yorke J; Molassiotis A
Health Qual Life Outcomes; 2020 Jul; 18(1):246. PubMed ID: 32703223
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy-induced peripheral neuropathy, physical activity and health-related quality of life among colorectal cancer survivors from the PROFILES registry.
Mols F; Beijers AJ; Vreugdenhil G; Verhulst A; Schep G; Husson O
J Cancer Surviv; 2015 Sep; 9(3):512-22. PubMed ID: 25876556
[TBL] [Abstract][Full Text] [Related]
31. Physical function as a predictor of chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer.
Lin KY; Chen PS; Lin CF
BMC Gastroenterol; 2024 May; 24(1):154. PubMed ID: 38711006
[TBL] [Abstract][Full Text] [Related]
32. Sensorimotor training and whole-body vibration training have the potential to reduce motor and sensory symptoms of chemotherapy-induced peripheral neuropathy-a randomized controlled pilot trial.
Streckmann F; Lehmann HC; Balke M; Schenk A; Oberste M; Heller A; Schürhörster A; Elter T; Bloch W; Baumann FT
Support Care Cancer; 2019 Jul; 27(7):2471-2478. PubMed ID: 30382392
[TBL] [Abstract][Full Text] [Related]
33. In Search of a Gold Standard Patient-Reported Outcome Measure for Use in Chemotherapy- Induced Peripheral Neuropathy Clinical Trials.
Smith EML; Knoerl R; Yang JJ; Kanzawa-Lee G; Lee D; Bridges CM
Cancer Control; 2018; 25(1):1073274818756608. PubMed ID: 29480026
[TBL] [Abstract][Full Text] [Related]
34. The psychometric properties of the Turkish version of the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool (CIPNAT).
Kutlutürkan S; Öztürk ES; Arıkan F; Kahraman BB; Özcan K; Uçar MA
Eur J Oncol Nurs; 2017 Dec; 31():84-89. PubMed ID: 29173832
[TBL] [Abstract][Full Text] [Related]
35. Motor disorders related to oxaliplatin-induced peripheral neuropathy: long-term severity and impact on quality of life.
Balayssac D; Kerckhove N; Selvy M; Pereira B; Gonneau C; Pétorin C; Vimal-Baguet A; Melnikov S; Kullab S; Hebbar M; Bouché O; Slimano F; Bourgeois V; Lebrun-Ly V; Thuillier F; Mazard T; Tavan D; Benmammar KE; Monange B; Ramdani M; Péré-Vergé D; Huet-Penz F; Bedjaoui A; Genty F; Leyronnas C; Pezet D; Martin V
Support Care Cancer; 2024 Jun; 32(7):427. PubMed ID: 38869647
[TBL] [Abstract][Full Text] [Related]
36. Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors.
Eckhoff L; Knoop A; Jensen MB; Ewertz M
Eur J Cancer; 2015 Feb; 51(3):292-300. PubMed ID: 25541155
[TBL] [Abstract][Full Text] [Related]
37. Development and psychometric evaluation of the chemotherapy-induced peripheral neuropathy assessment tool.
Tofthagen CS; McMillan SC; Kip KE
Cancer Nurs; 2011; 34(4):E10-20. PubMed ID: 21242773
[TBL] [Abstract][Full Text] [Related]
38. Electroacupuncture for chemotherapy-induced peripheral neuropathy: study protocol for a pilot multicentre randomized, patient-assessor-blinded, controlled trial.
Kim JH; Kim EJ; Seo BK; Lee S; Lee S; Jung SY; Lee MH; Kim AR; Park HJ; Shin MS; Choi SM
Trials; 2013 Aug; 14():254. PubMed ID: 23945074
[TBL] [Abstract][Full Text] [Related]
39. Assessing chemotherapy-induced peripheral neuropathy with patient reported outcome measures: a systematic review of measurement properties and considerations for future use.
Li T; Park SB; Battaglini E; King MT; Kiernan MC; Goldstein D; Rutherford C
Qual Life Res; 2022 Nov; 31(11):3091-3107. PubMed ID: 35596913
[TBL] [Abstract][Full Text] [Related]
40. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy.
Molassiotis A; Cheng HL; Lopez V; Au JSK; Chan A; Bandla A; Leung KT; Li YC; Wong KH; Suen LKP; Chan CW; Yorke J; Farrell C; Sundar R
BMC Cancer; 2019 Feb; 19(1):132. PubMed ID: 30736741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
